Australian Journal of Medical Herbalism - Clinical effects of Hibiscus sabdariffa on hypertension
Herrera-Arellano A, Miranda-Sanchez J, Avila-Castro P, Herrera-Alvarez S, Jimenez-Ferrer Jet al. 2007. Clinical Effects Produced by a Standardized Herbal Medicinal Product of Hibiscus sabdariffa on Patients with Hypertension. A Randomized, Double-blind, Lisinopril-Controlled Clinical Trial. Planta Med 73:6-12.
A clinical trial was carried out on 168 subjects aged 25-61 with stages 1 or 2 HT received either Hibiscus sabdariffa standardised to 250 mg of total anthocyanins or lisinopril 10 mg daily for 4 weeks. Effectiveness, safety, tolerability and success were determined. Serum Na, K, and Cl were measured as well as plasmatic ACE (angiotensin converting enzyme) activity.
Related Results
Mylan Receives Approval for Lisinopril and Lisinopril/HCTZIvax’s lisinopril gets tentative OKTeva Announces Approval Of Lisinopril Tablets And Lisinopril HCTZ TabletsGenerics firms win approval for lisinoprilEon Labs Receives Approval for Lisinopril/HCTZ Tablets
Both groups displayed a reduction in blood pressure however the lisinopril control group had a more significant decrease (15.79/15.68% compared to 11.58/12.21% decrease displayed by the H. sabdariffa group). The hibiscus group showed and increase in serum Cl by 3.42 meq/L and a decreased plasma Na by 2.04 meq/L, while K levels were not affected. The control group increased serum C1 by 2.87 meq/L. ACE activity was also reduced in both groups however this reduction was significantly higher in the lisinopril group.
This study indicated that H. sabdariffa exerts its antihypertensive effects through at least 2 modes of action, as a diuretic and as an ACE inhibitor. Alternative dosages need to be tested to determine if there is a dose dependant response.
Cara Barnes
20 Brendon Street, Tarragindi Qld 4121
COPYRIGHT 2007 National Herbalists Association of Australia
COPYRIGHT 2008 Gale, Cengage Learning
